Copeptin and Troponin

Instant and safe rule-out of myocardial infarction with a single blood sample

Copeptin, is a stable and sensitive surrogate marker for circulating AVP or anti diuretic hormone (ADH). As a marker of acute endogenous stress, Copeptin is increased immediately after the onset of Acute Myocardial Infarction and then steadily decreases.¹

Clinical benefits of the dual marker strategy:²⁻⁵

- 67% Instant rule-out with a single blood draw
- Up to 100% NPV Proved discharge
- -29% Cost savings in the acute setting
- -131 Minute shorter length of stay per patient
- -25% Cost savings during a hospital stay
- -49 Minute reduced stuff time per patient

References:
2. Lipinski MJ. et al., Am J Cardiol. 2014 May 1;113(9):1581-91.
B·R·A·H·M·S
Copeptin proAVP KRYPTOR

Patients with low to intermediate risk of acute coronary syndrome

Clinical assessment/GRACE score

Combined measurement of Troponin and Copeptin

Troponin negative and Copeptin negative (< 10 pmol/L)

Clinical assessment supports biomarker results

Discharge or early disposition

Troponin positive and/or Copeptin positive (> 10 pmol/L)

Clinical assessment recommends further investigations

Standard care with serial Troponin measurements


Find out more at thermoscientific.com/copeptin

Thermo Fisher Scientific · B·R·A·H·M·S GmbH · Neuendorfstr. 25
16761 Hennigsdorf/Germany · info.copeptin@thermofisher.com

Product is CE marked but not 510(k)-cleared and not [yet] available for sale in the U.S. Availability of product in each country depends on local regulatory marketing authorization status.

© 2020 Thermo Fisher Scientific Inc. All rights reserved.
All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. KRYPTOR and TRACE are trademarks of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific.